Bicarbonate

Bicarbonate

SCHEMBL14917

O=C(O)O.O=C1CCC(=O)N1O

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.38
CA9 Q16790 2/20 0.38
CA12 O43570 1/20 0.38
ALDH1A1 P00352 2/20 0.32
PKM P14618 1/20 0.32
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
MAPK1 P28482 1/20 0.31
KDM4E B2RXH2 2/20 0.31
GAA P10253 1/20 0.31
POLB P06746 1/20 0.31
CA2 P00918 1/20 0.31
LMNA P02545 1/20 0.31
TSHR P16473 1/20 0.30
PARL Q9H300 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL6150295 1.00 CA1 (0.38) CA1CA9CA12ALDH1A1PKM
Oxalic Acid SCHEMBL9728851 0.91 CA12 (0.37) CA1CA9CA12ALDH1A1PKM
SCHEMBL338264 0.90 KDM4E (0.34) CA1CA9CA12ALDH1A1KDM4E
SCHEMBL785147 0.90
SCHEMBL1123 0.90
SCHEMBL6742810 0.88 CA12 (0.35) CA1CA9CA12ALDH1A1PKM
Acetic Acid SCHEMBL21834859 0.88 FFAR3 (0.39) CA1CA9CA12ALDH1A1PKM
Acetic Acid SCHEMBL482738 0.88 FFAR3 (0.39) CA1CA9CA12ALDH1A1PKM
Carbamic Acid SCHEMBL699756 0.88 ACHE (0.39) CA1CA9CA12ALDH1A1PKM
SCHEMBL25175816 0.87

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114438047-B Method for preparing polyethylene glycol modified urate oxidase 重庆派金生物科技有限公司 2024-11-22 CN claimed
CN-114438048-B Urate oxidase preparation and application thereof 重庆派金生物科技有限公司 2024-10-22 CN claimed
CN-118497161-A Polyethylene glycol modified urate oxidase 重庆派金生物科技有限公司 2024-08-16 CN claimed
CN-118453890-A Composition for improving stability of polyethylene glycol asparaginase, pharmaceutical composition and application thereof 重庆派金生物科技有限公司 2024-08-09 CN claimed
CN-117866929-A Pegylated arginine deiminase dimer preparation and use thereof 重庆派金生物科技有限公司 2024-04-12 CN claimed
CN-116966279-A Covalently modified recombinant phenylalanine lyase enteric-coated preparation and application thereof 重庆派金生物科技有限公司 2023-10-31 CN claimed
CN-115869456-A Preparation of in-situ gelation anti-swelling enhanced tissue adhesive material 上海其胜生物制剂有限公司 2023-03-31 CN claimed
CN-114805540-A Long-acting adrenomedullin derivative 国立大学法人宫崎大学 2022-07-29 CN claimed
WO-2022095973-A1 URATE OXIDASE PREPARATION AND USE THEREOF 杭州远大生物制药有限公司 2022-05-12 WO claimed
WO-2022095974-A1 METHOD FOR PREPARING POLYETHYLENE GLYCOL-MODIFIED URATE OXIDASE 杭州远大生物制药有限公司 2022-05-12 WO claimed
CN-114438047-A Method for preparing polyethylene glycol modified urate oxidase 重庆派金生物科技有限公司 2022-05-06 CN claimed
CN-114438048-A Urate oxidase preparation and application thereof 重庆派金生物科技有限公司 2022-05-06 CN claimed
WO-2020228618-A1 POLYETHYLENE GLYCOL-MODIFIED URATE OXIDASE 重庆派金生物科技有限公司 2020-11-19 WO claimed
CN-111909906-A Urate oxidase modified by polyethylene glycol 重庆派金生物科技有限公司 2020-11-10 CN claimed
US-20030114647-A1 Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules SHEARWATER CORPORATION 2003-06-19 US claimed
US-20010007765-A1 MULTI-ARMED, MONOFUNCTIONAL, AND HYDROLYTICALLY STABLE DERIVATIVES OF POLY (ETHYLENE GLYCOL) AND RELATED POLYMERS FOR MODIFICATION OF SURFACES AND MOLECULES NEKTAR THERAPEUTICS 2001-07-12 US claimed
JP-6340603-A None JP disclosed
US-12544491-B2 In situ forming hemostatic foam implants ARSENAL MEDICAL, INC. (US) 2026-02-10 US disclosed
EP-0094815-A2 Oligopeptide prodrugs SMITHKLINE BECKMAN CORPORATION (US) 1983-11-23 EP disclosed
US-3965089-A Process for the production of a cyclic ureido-derivative of a deoxystreptamine-containing antibiotic and products thereof ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) 1976-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12544491-B2 In situ forming hemostatic foam implants F9, F12, F2 CA1 2365/4885CA9 1594/4885CA12 1035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.